Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial demonstrated that 92 percent of evaluable patients treated with INB-200 exceeded a median ...

One patient has glioblastoma multiforme (GBM), and the other patient has advanced hepatocellular carcinoma (HCC) treated in ...

McCain has decided to discontinue treatment, his family said. — -- Sen. John McCain has decided to discontinue treatment of his brain cancer, his family said Friday. McCain was diagnosed last ...

(RTTNews) - Novocure (NVCR) an oncology company, has received approval from the FDA for its new Head Flexible Electrode transducer arrays, designed for use with its Optune Gio device, which is used in ...

April 26, 2006 (San Francisco) --- Glioblastoma multiforme patients treated with a peptide vaccine after gross total resection and standard therapy have a median survival beyond 18 months, researchers ...

Newco Trogenix Ltd. has emerged from incubation and raised £70 million (US$94.1 million) in a series A, as it prepares the ground for a U.S/U.K. clinical trial of a novel gene therapy construct in ...

The most common and aggressive type of adult brain cancer, glioblastoma multiforme (GBM) is notoriously resistant to treatment, with a median survival of just 14 months following diagnosis. Its ...

This survival data along with radiographic improvements are indicative of positive treatment effects, which highlights the potential of IN8bio’s genetically modified, chemotherapy-resistant ...

Newly discovered oncology drugs called “DNA-encoded tri-specific T-cell engagers,” or “DTriTEs,” engage the immune system more effectively than traditional therapies, particularly against evasive and ...